We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vistagen Therapeutics Inc | NASDAQ:VTGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03 | 0.67% | 4.48 | 4.38 | 4.58 | 4.58 | 4.3901 | 4.51 | 153,524 | 00:22:49 |
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Virtual CNS Days taking place March 19 to 20, 2024.
Stifel 2024 Virtual CNS Days
A webcast will be accessible through the “Events” page in the “Investors” section of the Company’s website at www.Vistagen.com. Investors interested in arranging a one-on-one meeting during the conference should contact their Stifel representative.
About Vistagen
Vistagen (Nasdaq: VTGN) is a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. Five of Vistagen’s clinical-stage neuroscience pipeline candidates belong to a new class of drugs known as pherines, which are investigational neuroactive nasal sprays with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neural circuitry in the brain without the need for systemic absorption or binding to receptors in the brain. Vistagen’s sixth investigational candidate is an oral prodrug with potential to inhibit, but not block, NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders. Connect at www.Vistagen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311902490/en/
Investors: Mark A. McPartland (650) 577-3606 markmcp@vistagen.com
Media: Caren Scannell (650) 577-3601 cscannell@vistagen.com
1 Year Vistagen Therapeutics Chart |
1 Month Vistagen Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions